TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
44 hedge funds and large institutions have $58.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 42 → 44 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
42% less call options, than puts
Call options by funds: $130K | Put options by funds: $225K
42% less capital invested
Capital invested by funds: $101M → $58.4M (-$42.9M)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$505K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$397K |
| 3 |
TI
Telemetry Investments
New York
|
+$277K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$227K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$728K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$588K |
| 3 |
Renaissance Technologies
New York
|
-$464K |
| 4 |
Millennium Management
New York
|
-$426K |
| 5 |
Two Sigma Investments
New York
|
-$411K |
TCON Hedge Fund Activity: Q2 2021 in Review
44 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2021, worth a combined $58.4M — down 42% from $101M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TCON positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 14 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $505K. The largest seller was Ameriprise, exiting entirely with an estimated $728K sold.
- 44 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2021, up from 42 in Q1 2021.
- Funds reported $58.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 42% quarter-over-quarter.
- 7 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 5 closed out, a net change of +2 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was State Street, an estimated $505K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Ameriprise, an estimated $728K sold.
Based on aggregated 13F filings for Q2 2021.